Inovio Pharmaceuticals Financial Results
INOVIO reported Q3 2026 financial results and highlighted the landmark FDA accelerated approval of VOCERYQ, the first-ever approved DNA medicine, for the treatment of Recurrent Respiratory Papillomatosis (RRP). The company recently completed a public offering raising $80.5 million in net proceeds to support the commercial launch of VOCERYQ, which is expected to be available for order in early 2027.
“We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
“Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer